Results 11 to 20 of about 545,624 (314)
Journal of Clinical Oncology, 2021 PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors.
Keunchil Park +33 more
semanticscholar +1 more source
A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations
Diagnostics, 2020 The detection of EGFR mutations in circulating cell-free DNA can enable personalized therapy for cancer. The current techniques for detecting circulating EGFR mutations are expensive and time-consuming with moderate sensitivity.
Jen-Hui Tsou, Qixin Leng, Feng Jiang
doaj +1 more source
Water-soluble pristine C60 fullerene attenuates acetaminophen-induced liver injury [PDF]
BioImpacts, 2019 Introduction: Oxidative stress has been suggested as the main trigger and pathological mechanism of toxic liver injury. Effects of powerful free radical scavenger С60 fullerene on rat liver injury and liver cells (HepG2 line) were aimed to be discovered.
Halyna Kuznietsova +6 more
doaj +1 more source
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Nature Reviews Clinical Oncology, 2022 The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment paradigm for patients with advanced-stage disease.
Alissa J Cooper +2 more
semanticscholar +1 more source
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
New England Journal of Medicine, 2020 BACKGROUND Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Yi-long Wu +23 more
semanticscholar +1 more source
International Journal of Molecular Sciences, 2023 Epidermal growth factor receptors (EGFRs) are a class of receptor tyrosine kinase that are also called ErbB1 and HER1. EGFR tyrosine kinase activity inhibition is considered a promising therapeutic strategy for the treatment of cancer.
Tanzida Zubair, D. Bandyopadhyay
semanticscholar +1 more source
Journal of Hematology & Oncology, 2022 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations.
Kai Fu, Fa Xie, Fang Wang, Liwu Fu
semanticscholar +1 more source
EGFR signaling pathway as therapeutic target in human cancers.
Seminars in Cancer Biology, 2022 Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand orchestrator of epithelial transformation, and hence one of the most world-wide studied ...
E. Levantini +3 more
semanticscholar +1 more source
Clinical Journal of the American Society of Nephrology, 2008 Reporting estimated glomerular filtration rate (eGFR) with serum creatinine simply provides the information for which the serum creatinine was ordered in the first place. Mass or universal screening is not the purpose of eGFR reporting. Furthermore, such mass screening does not seem justified.
Michal L, Melamed +2 more
openaire +3 more sources
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
New England Journal of Medicine, 2019 BACKGROUND Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.
S. Ramalingam +23 more
semanticscholar +1 more source